You are here: Industry Insights > Merck

News List

Pfizer Says New COVID-19 Pill Cuts Severe Disease by 89 Percent Drugs
November 08, 2021
Pfizer Inc. announced Friday that its experimental COVID-19 pill slashed the risk of hospitalization and death by 89 percent in infected high-risk people.
UK grants world-first approval to Covid-19 pill molnupiravir Pharmaceutical-Technology
November 05, 2021
The first oral antiviral to treat Covid-19, Merck and Ridgeback Biotherapeutics’ molnupiravir, has been approved by the UK drugs regulator.
UK Authorizes Merck, Ridgeback’s Oral COVID Antiviral Molnupiravir ContractPharma
November 05, 2021
Merck and Ridgeback Biotherapeutics received authorization in the UK for molnupiravir (MK-4482, EIDD-2801), the first oral antiviral medicine authorized for the treatment of mild-to-moderate COVID-19...
Merck and MPP sign licence deal for oral antiviral Covid-19 drug Pharmaceutical-Technology
October 29, 2021
Merck (MSD) and the Medicines Patent Pool (MPP) have entered a voluntary licencing agreement to offer affordable international access for the former’s experimental oral antiviral, molnupiravir (MK-4482/EIDD-2801), to treat Covid-19.
Merck Allows Poor Nations to Make COVID-19 Pill Drugs
October 28, 2021
A deal for the Merck COVID-19 pill to be made and sold cheaply in poor nations has been reached with Medicines Patent Pool, a United Nations-backed nonprofit organization.
Ontada Signs Strategic Agreement with Merck to Facilitate the Development of Data-Driven Insights to Impact Quality of Cancer Care firstwordpharma
August 27, 2021
OntadaTM, McKesson's oncology and insights business, today announced a strategic agreement with Merck, known as MSD outside the United States and Canada, that will facilitate the development of real-world research excellence and innovation.
Leslie A. Brun Resigns from Merck Board of Directors firstwordpharma
August 23, 2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Leslie A. Brun, its independent lead director, has resigned from its Board of Directors, effective August 19, 2021.
Merck Canada Initiates Rolling Submission to Health Canada for Molnupiravir, an Investigational Oral Therapeutic Agent for the Treatment of COVID-19 firstwordpharma
August 16, 2021
Merck, known as MSD outside the United States and Canada, today announced the initiation of a rolling submission to Health Canada for molnupiravir, an investigational twice daily oral antiviral agent currently in trials as a potential treatment.
Merck’s Keytruda receives FDA priority review in renal cell cancer pharmaceutical-technology
August 12, 2021
The US Food and Drug Administration (FDA) has granted priority review to Merck’s (MSD) new supplemental biologics license application (sBLA) for Keytruda (pembrolizumab) as adjuvant therapy to treat renal cell carcinoma (RCC) patients.
ClinTex (CTi) launches CTi-OEM blockchain clinical trial app expresspharma
August 06, 2021
The ClinTex (CTi) tokenised platform will utilise blockchain-based clinical data analytics to address the main causes of clinical trial inefficiency, helping to drive down the cost of new medicines and expediting their delivery to patients ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page